This site is intended for healthcare professionals practicing in the US.
©2025 AstraZeneca. All rights reserved.
US-69609; US-91816; US-103094; US-106788
Last Updated 11/25
WEBSITE
WEBSITE
HER2 IHC Testing in Solid Tumors
VIDEO
Although most patients with TNBC are diagnosed in the early-stage curative setting, significant unmet needs remain despite advancements in targeted treatments. It is essential to raise HCP awareness around these patients, who require more efficacious and tolerable therapy options compared to the current standard of care. Additionally, there is growing recognition of the need to enhance patient-centred care beyond treatment, addressing psychological well-being, social support and survivorship as integral components in the management of TNBC.
Explore the patient journey and unmet needs for patients with eTNBC with insights from Matteo Lambertini, an Associate Professor and Consultant in Medical Oncology, whose research specialises in breast cancer care, with a particular focus on the management of breast cancer and fertility preservation.
VIDEO
Despite a number of exciting targeted-treatment advances in TNBC over the last decade, the majority of patients with mTNBC do not express the biomarkers necessary to benefit from these therapies, and even those who do may still be ineligible for treatment. Enhancing healthcare professionals' awareness of these patients' needs is essential as we strive for more effective and tolerable treatmentoptions.
Explore the unmet needs for patients with first-line mTNBC treatment with insights from Paolo Tarantino, a breast medical oncologist and clinical researcher, whose research focusses on the HER2 oncoprotein and the development of novel therapies that target multiple subtypes, including TNBC.
VIDEO
VIDEO
This video is a series of 3D animated videos on HER2 mutations in NSCLC.
The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.
This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.
Are you a healthcare professional practicing in the United States?